tiaea/week.11 petients received treatment during 4 full yrs.:6 in 01(r01) and 5 in 02(r02).The 8ean Chronological Aga(CA),Bone Age(BA),Height(Ht)SOSaend BA.SOS were coaparable in both groups at the onset of treatsent. 1.-The evolution of height showed that in 02/r02 the ic reasa in SOS was significantly highar than in 01/r01 through the traatsent.The cstch-up period was 3 yrs. in 01/r01 and it was still praaent in 02/802 in tha 4th y2
.-ln 01/r01 the BA increasad parallaly to tha CA,buti. tha 02/r02 thera waS a continuoua catch-up of BA with BA)CA in tha 4th yr. 3.-Tha relationahip4Ht/ABA was: tHt.SOS01 1 4S·AHt.SOS02 1 2·tHt.SDSDz:~t.SOS01
4A.50501 • 'ABA. 50502 .1, A.5OS0rAA.5050,-0.B1.
Uhathar this axp8Ctad aarly bona fusion using tha 02 doaaga is dua to tha hGH itsalf or to a contaaination by TSH/Gonadotrophins ie now being investigated.
·505 • Standard Deviation Scare
L. FRYKLUND*, K. F~OLENHAG*, B.*HOLMSTROM*, A. SK~TTNER-LUNDIN , A. WICHMAN , and H. FLODH (Intr. by Prof. K. Hall), KabiVitrum AB, S-112 87 Stockholm, Sweden . Biosynthetic human growth hormone produced in E. coli.
The gene for human pituitary somatotropin (hGH) has been inserted into the plasmid PBr 322 in E.coli Kl2 by recombinant DNA techniques. The recombinant bacter a have been grown in batch culture and the hGH extracted from the disintegrated cells. Conventional biochemical separation methods such as ion exchange and gel chromatography have been used for purification in a scale suitable for industrial production.
The biosynthetic hGH appears to be identical with regards to molecular weight and sequence with the exception of an N-terminal methionine. No contaminating proteins are present. Biological activity, determined by weight gain in hypophysectomized rats and sulfate incorporation into connective tissue appears to be identical to that of the pitu itary hormone. Extensive toxicoligical studies suggest that the product should be safe for human use.
We conclude that the biosynthetic human growth hormone is comparable to the pituitary hormone and this product once available should alleViate the shortage of hormone for the treatment of hypopituitary dwarfism.
A New Improved Method for Collecting Samples for Somatomedin C Determin..ti on.
The current specimen collection for the determination of Somatomedin C requires venipuncture, centrifugation, then serum or plasma sep4ration followed by shipment to a laboratory performing the assay. Collection of capillary blood on specially prep4r-ed filter paper followed by air drying and mailing to the laboratory, removes all the steps of the traditional approach. Upon receipt by the laboratory, a l/S" disc is cut in the dot and the blood eluted by a buffer. The volume of blood in the l/S" dot is 0.15 microliters of plasma (Neonatal Screening programs) . The radioimmunoassay is then performed using second antibody separation technique following a sequential immunoassay using a rabbit anti-somatomedin C antibody and 1251 somatomedin C. The To atudy the affect of chronic administration of L-Dopa on growth 10 paira of rata, ..tchea by sibship and sex vere injected Dopa. or ..line s.c. tvice daily, frca , to l' veeks of age. Pair feeding .... aaaured.
At l' veeks, after 2 days off treataent the ani..l vere ..crificed.
Blood vas collected for CII RIA and the th7lll\l8, thyroid, adrenala, uterus and gonads veighed.
Female and ..Ie rats grev significantly better on L-Dopa:
,
}Oa2 17=.5 180=9~=.7 206=15 37=.2 Dopa '1=2 17=.5 207=14~=.5 242=14 ,?=., 1Ia1. Con.
,sa' 18=.2 272=6 ,s=1.,~5=14 41=.8 Dopa 37..' 18=.'~=12 40=.2~2=14 4'=.6 Serum GB .... 8.44"1.4ng/al in the Dopa and 4.6=0.9 in tbe control group.
All organa veighed tended to be huner in the Dopa group, though not aignificant~.
In conclu.ion: Chronic administration ot L-Dopa produce a chronic atbllllation of Gil secretion and enhances growth in ..Ie and in feaale rats.
Evidence for the presence in human serum of an ultrafiltrable factor act ivat ing somatomed ins Human serum contains an ultrafiltrable factor (350 < M.W. < 700) which stimulates sulphation activities of native, or purified somatomed in A of either small or hig, molecular weight. The factor is heat s Seoretion of oaloitonin and parathyroid hormone by embryonal oaroino.. oella I variationa vith ditterentiation.
Difterentiation ot teratooaroino.. cella in oulture allov. to atud7 oertain aspects ot the early eabryogeneaia. The adenylate oyolaae ayatea ot oultured F9 oella ia apeoitically atimulated by oaloitonin. Ditferentiation into endodereal oella by treatment vith retinoio aoid ia folloved by a loaa of oaloitonin reaponaiveneaa and the appearanoe of parathTroid hormone atiaulation of the oyolaae ayatem. In addition radioimaunologioal and biologioal aotive foraa ot oaloitonin are seoreted by F9 oella in the oulture medium. Along vith ditferentiation vith retinoio aoid a progreaaive deoreaae ot oaloitonin aeoretion ia obaerved latter 4 daya of treatsent no oaloitonin ia any longer deteotable. But at thia atage of differentiation a parath7roid hormone-like aubatanoe ia radioiaaunologioally and biologioally deteotabla. Theae apaoitio ohangea in hormonal aeoretion and reoeptivity oan be ueed aa marker. ot ditferentiation. Theae reaulta alao auggaat a poaaible role for Caloitonin and Parath7rotd hormone-like aotivitiea during the initial ateps ot embryogeneaia.
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